BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$2.57 USD
+0.01 (0.39%)
Updated May 3, 2024 04:00 PM ET
After-Market: $2.58 +0.01 (0.39%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BTAI 2.57 +0.01(0.39%)
Will BTAI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BTAI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BTAI
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMIā¢
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
BioXcel announces plan for evaluating BXCL501 in at-home setting
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)